Search Results

Biotech Bay

Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma

ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only methylprednisolone (MP) well tolerated and shows efficacy for treating heavily previously treated multiple myeloma (MM) patients.

December 20, 2022

·

3 min read

Biotech Beach

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020

- ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only steroids is well tolerated and shows promising efficacy for treating heavily previously treated MM patients.

January 20, 2021

·

2 min read

Drug Development

Human Papillomavirus (HPV)-induced Cancers: First Patient Enrolled in Phase I/IIa Clinical Trial for Lenti-HPV-07, the TheraVectys’ Therapeutic Vaccine Candidate Against Oropharyngeal and Cervical Cancers

October 4, 2024

·

8 min read

BioCapital

US Medical Innovations to Present at the JMP Securities Life Sciences Conference

US Medical Innovations, LLC, announced that Jerome Canady MD, Chief Executive Officer, USMI, will be presenting “Cold Plasma Oncotherapeutics™ and Robotic Voice-Operated Delivery System.

June 6, 2019

·

1 min read

A park in Houston with skyscrapers in the backgrou

Drug Development

Biotech Accelerator Debuts in Houston

The new Rice Biotech Launch Pad aims to harness local resources to grease the skids of innovation, from the lab to the clinic.

October 18, 2023

·

3 min read

·

Charlotte LoBuono

BioCapital

USMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) are pleased to announce today a ground-breaking achievement in surgical and robotic technology.

September 22, 2023

·

3 min read

Policy

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

ImmunityBio, Inc., an immunotherapy company, announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy and standard-of-care chemotherapy to be discussed during the upcoming conference call.

April 25, 2024

·

11 min read

Drug Development

Oncotherapeutics Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results

February 12, 2009

·

2 min read

Business

Oncology CRO Oncotherapeutics Selects David Donahue as New Senior Director of Clinical Operations in Los Angeles, California

June 11, 2009

·

1 min read

Policy

Jerome Canady Research Institute for Advanced Biological and Technological Sciences Discovers Regulatory Gene BCL2A1 for Treatment of Triple-Negative Breast Cancer

The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), announced today that their recent article, “BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER (TNBC)”, has been published in Scientific Reports, a Nature Portfolio journal.

March 15, 2022

·

2 min read